New generation estrogen receptor:- Announcing a new publication for Acta Materia Medica journal.[Pixabay] 
Health

New generation estrogen receptor-targeted agents in breast cancer

Announcing a new publication for Acta Materia Medica journal. Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor.

NewsGram Desk

New generation estrogen receptor:- Announcing a new publication for Acta Materia Medica journal. Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor.

However, the issue of drug resistance poses a significant clinical challenge. It is therefore critically important to create new therapeutic agents that can suppress ERα activity, particularly in cases of ESR1 mutations.

This review article highlights recent efforts in drug development of next generation ER-targeted agents, including oral selective ER degraders, proteolysis-targeting chimera ER degraders, and other innovative molecules, such as complete estrogen receptor antagonists and selective estrogen receptor covalent antagonists.

The drug design, efficacy, and clinical trials for each compound are detailed. AlphaGalileo/SP

Can Simpsons actually predict the future?

Pune’s Irani Immigrant who pioneered Soft Drinks long before Coca Cola and Pepsi dominated

Why did doctors wear bird masks during the Black Death?

Toxic Childhood? Study Uncovers Broad Chemical Exposure in U.S. Preschoolers

5 tips to keep your hearing sound